Pharming Group reports third quarter 2023 financial results Third quarter 2023 revenues increased 23% to US$66.7 million, compared to the third quarter 2022, driven by RUCONEST® revenue and the U.S. commercial launch of Joenja®Nine month year to date 2023 revenues increased 9% to US$164.1 million, compared to nine month year to date 2022RUCONEST® revenues increased 11% in the third quarter 2023 to US$60.2 million, compared to the third quarter 2022, and increased 18% compared to the second quart
Pharming Group N V : Pharming Group reports third quarter 2023 financial results finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Pharming Group N V : Pharming Group reports second quarter and first half 2023 financial results finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
RUCONEST® business performed strongly in 2Q 2023; continue to anticipate low single digit annual revenue growth Strong start to U.S. Joenja® launch during 2Q.
/PRNewswire/ ACM Biolabs, a biotechnology company with operations in Singapore, Switzerland and Australia, focusing on the development of next generation.